Cover Image

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review

Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma (MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant attention in MM therapeutic research. Venetoclax (VTC), a small-molecule targeted agent, effectively inhibits BCL-2, promot...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qiang Cao (Author), Xinyan Wu (Author), Qi Zhang (Author), Junling Gong (Author), Yuquan Chen (Author), Yanwei You (Author), Jun Shen (Author), Yi Qiang (Author), Guangzhu Cao (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A literature review: mechanisms of antitumor pharmacological action of leonurine alkaloid
by: Qiang Cao, et al.
Published: (2023)

Synergistic effect of venetoclax and teglicar in multiple myeloma cell lines
by: Belal A. Al-Husein, et al.
Published: (2024)

Muscle quality index is associated with trouble sleeping: a cross-sectional population based study
by: Yanwei You, et al.
Published: (2023)

Mitigation role of physical exercise participation in the relationship between blood cadmium and sleep disturbance: a cross-sectional study
by: Yanwei You, et al.
Published: (2023)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
by: Qingfang Li, et al.
Published: (2019)

PP 8.9 - 00142 Safety and activity of BCL-2 inhibitor Venetoclax in uninfected rhesus macaques
by: T. Wiche Salinas, et al.
Published: (2022)

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
by: Andrea Ceglédi, et al.
Published: (2023)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023)

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
by: Vincenzo Raimondi, et al.
Published: (2022)

Dysregulation of BCL-2 family proteins in blood neoplasm: therapeutic relevance of antineoplastic agent venetoclax
by: Faris Tayeb
Published: (2024)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
by: Yaohua Cao, et al.
Published: (2021)

OP 1.8 - 00204 Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir
by: Y. Kim, et al.
Published: (2022)

Multidimensional role of adapalene in regulating cell death in multiple myeloma
by: Xinya Cao, et al.
Published: (2024)

Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
by: Ali N. Kamali, et al.
Published: (2024)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Noah M. Merin, et al.
Published: (2014)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
by: Domenico Ribatti
Published: (2010)

The prognostic significance of ubiquitination-related genes in multiple myeloma by bioinformatics analysis
by: Feng zhang, et al.
Published: (2024)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
by: Pan Zhou, et al.
Published: (2022)

Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
by: Marta Pelon, et al.
Published: (2024)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
by: Tandon N, et al.
Published: (2016)

Multiple Mechanisms for the Action of Chymase Inhibitors
by: Shinji Takai, et al.
Published: (2012)

Multiple Myeloma
Published: (2021)

Multiple Myeloma An Overview
Published: (2012)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
by: Joelle C. Boulos, et al.
Published: (2021)

Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta‐analysis
by: Congcong Cao, et al.
Published: (2021)

Village doctors' dilemma in China: A systematic evaluation of job burnout and turnover intention
by: Yuquan Chen, et al.
Published: (2022)

Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor
by: Ahmed Hamed Salem, et al.
Published: (2024)

Update on Multiple Myeloma
Published: (2019)

Immunotherapy in Multiple Myeloma
Published: (2019)

Integrins in multiple myeloma
by: Naoki Hosen
Published: (2020)

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS
by: Yuan Peng, et al.
Published: (2024)

Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
by: Qian Li, et al.
Published: (2018)

Mechanism of action of Asparagus officinalis extract against multiple myeloma using bioinformatics tools, in silico and in vitro study
by: Yanju Li, et al.
Published: (2023)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
by: Amber Loren O. King, BA, et al.
Published: (2021)

Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients
by: Xi Wang, et al.
Published: (2022)

Multiple Myeloma A Quick Reflection on the Fast Progress
Published: (2013)

Recent Updates on Multiple Myeloma
Published: (2023)